Performance of Dark Chemical Matter in High Throughput Screening.

A statistical analysis of 203 high-throughput screens was conducted studying the propensity of small molecules in the Boehringer Ingelheim screening deck to show biological activity after having tested as inactive previously in a growing number of screening assays. Dark chemical matter (DCM) compounds, which have been tested and found to be inactive in 50 or more assays, exhibit hit rates that are comparable to those of compounds tested in much fewer assays. Only compounds tested as inactive in 125 or more assays started showing a hit rate deterioration of up to 40% compared to compounds tested in less than 25 assays. The observed large number of DCM compounds in the BI screening deck is found to be in line with the expected fraction of DCM calculated based on a probability analysis. The analysis suggests not only that DCM compounds have the chance to occasionally provide valuable hits associated with higher selectivity as recently shown by Novartis ( Nat. Chem. Biol. 2015 , 11 , 958 ) but that there is little compelling reason to exclude DCM compounds from screening decks in favor of previously untested or less tested compounds.

[1]  Anne Mai Wassermann,et al.  Dark chemical matter as a promising starting point for drug lead discovery. , 2015, Nature chemical biology.

[2]  Stefan Schmitt,et al.  Stratified High-Throughput Screening Sets Enable Flexible Screening Strategies from a Single Plated Collection , 2014, Journal of biomolecular screening.

[3]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[4]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[5]  Andrew Bell,et al.  Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..

[6]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[7]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[8]  Dragos Horvath,et al.  Design of a General‐Purpose European Compound Screening Library for EU‐OPENSCREEN , 2014, ChemMedChem.

[9]  Gregory A. Bakken,et al.  A Heuristic Algorithm for Plate SelectionThat Maximizes Compound Diversity , 2013 .

[10]  Andreas Bender,et al.  “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.

[11]  Anne Mai Wassermann,et al.  Biodiversity of small molecules--a new perspective in screening set selection. , 2013, Drug discovery today.

[12]  Thorsten Nowak,et al.  Expanding medicinal chemistry space. , 2013, Drug discovery today.

[13]  R. Spencer,et al.  High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.

[14]  S. P. Fodor,et al.  Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. , 1994, Journal of medicinal chemistry.

[15]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[16]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[17]  Anil Vasudevan,et al.  Abbott Physicochemical Tiering (APT)--a unified approach to HTS triage. , 2012, Bioorganic & medicinal chemistry.

[18]  Jérôme Hert,et al.  Quantifying Biogenic Bias in Screening Libraries , 2009, Nature chemical biology.

[19]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[20]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[21]  I. Muegge Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.